What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce and detail the terms of a new Employment Agreement entered into by LAM RESEARCH CORP (LRCX) with its Executive Vice President, Patrick J. Lord. This agreement replaces a previous Change in Control agreement and outlines his compensation, responsibilities, and severance benefits.

What are the key financial components of Dr. Lord's new employment agreement?

Dr. Lord's agreement includes a base salary of $509,850, annual reviews for potential adjustments, and eligibility to participate in short-term and long-term variable compensation programs offered to other executives. He is also eligible for the Company's Elective Deferred Compensation Plan and other standard executive benefits like health insurance.

What happens to Dr. Lord's compensation and equity if his employment is terminated?

The agreement specifies different outcomes based on termination type. For involuntary termination (not related to a change in control), he receives 12 months' base salary, 50% of his average last five annual short-term incentive payments, pro-rata short-term incentives for the termination year, payment for accrued long-term cash compensation, medical benefits, pro-rata vesting of certain unvested equity (RSUs, options, mPRSUs, PRSUs). In case of a Change in Control followed by an involuntary termination within 18 months, he receives 18 months' base salary, 150% of his average last five annual short-term incentive payments, a prorated short-term incentive, medical benefits, full vesting of outstanding RSUs/options, and accelerated payment of long-term cash programs.

What are the implications of a voluntary resignation or termination due to disability/death?

If Dr. Lord voluntarily resigns, he is generally entitled to no additional benefits beyond what might be available under Retiree Health Plans, and unvested stock options/RSUs will cease to vest or be canceled. In the event of termination due to disability or death, he or his estate will receive pro-rata short-term incentives, accrued long-term cash compensation, medical benefits, and at least 50% (or a pro-rata amount if greater) vesting of unvested stock options, RSUs, mPRSUs, and PRSUs.

LRCX 8-K: Leadership Changes

Summary

LAM RESEARCH CORP (LRCX) filed an 8-K on September 8, 2020, to disclose the execution of a new Employment Agreement with Patrick J. Lord, effective September 8, 2020. This agreement replaces his prior Change in Control Agreement and sets his term as Executive Vice President through December 31, 2020, aligning with other executive end dates. The agreement details Dr. Lord's base salary, eligibility for variable compensation and deferred compensation plans, and outlines specific severance packages contingent on the circumstances of his employment termination, including involuntary termination, change in control scenarios, disability, or death. Investors should note the comprehensive severance provisions, particularly those triggered by involuntary termination or a change in control. These provisions include significant cash payments, accelerated vesting of equity awards (restricted stock units and options), and continued medical benefits, suggesting the company's commitment to retaining and providing for key executive talent. The agreement also clarifies benefits upon voluntary resignation, disability, or death, and includes customary confidentiality and non-competition clauses, alongside a requirement for a release to receive severance.

Key Highlights

1LRCX entered into a new Employment Agreement with Executive Vice President Patrick J. Lord, effective September 8, 2020.
2The agreement replaces Dr. Lord's previous Change in Control Agreement.
3Dr. Lord's term as Executive Vice President is set to end on December 31, 2020, aligning with other executive agreements.
4The agreement details Dr. Lord's base salary of $509,850 and participation in executive compensation and deferred compensation plans.
5Significant severance benefits are outlined for involuntary termination, including salary continuation, pro-rata short-term incentives, and accelerated equity vesting.
6Enhanced severance is provided in the event of a Change in Control combined with an Involuntary Termination, including longer salary continuation and increased incentive payouts.
7Provisions for termination due to disability or death include pro-rata incentives, accrued long-term compensation, medical benefits, and partial accelerated vesting of equity awards.

LAM RESEARCH CORP 8-K Report, Executive Changes (Sep 8, 2020)

Summary

Key Highlights

Frequently Asked Questions